Major histocompatibility complex class II+B7-1+ tumor cells are potent vaccines for stimulating tumor rejection in tumor-bearing mice.
Mice carrying large established major histocompatibility complex (MHC) class 1+ sarcoma tumors can be successfully treated by immunization with genetically engineered sarcoma cells transfected with syngeneic MHC class II plus B7-1 genes. This approach is significantly more effective than previously described strategies using cytokine- or B7-transduced tumor cells which are only effective against smaller tumor loads, and which cannot mediate regression of longer-term established tumors. The most efficient tumor rejection occurs if both the class II and B7-1 molecules are coexpressed on the same tumor cell. Immunity induced by immunization with class II+B7-1(+)-transfected sarcoma cells involves CD4+ and CD8+ T cells, suggesting that the increased effectiveness of the transfectants is due to their ability to activate both of these T cell populations.
Department of Biological Sciences, University of Maryland, Baltimore 21228.
S
S
Baskar
L
L
Glimcher
N
N
Nabavi
R T
RT
Jones
S
S
Ostrand-Rosenberg
D000818:Animals; D002478:Cells, Cultured; D005260:Female; D000949:Histocompatibility Antigens Class II / Q000235:genetics / Q000276:immunology / Q000627:therapeutic use*; D007167:Immunotherapy; D008297:Male; D051379:Mice; D008819:Mice, Nude; D012513:Sarcoma, Experimental / Q000276:immunology / Q000628:therapy*; D014162:Transfection; D014614:Vaccines, Synthetic / Q000276:immunology / Q000627:therapeutic use
D000949:Histocompatibility Antigens Class II; D014614:Vaccines, Synthetic